Market Trends of Global Pericarditis Drugs Industry
This section covers the major market trends shaping the Pericarditis Drugs Market according to our research experts:
Nonsteroidal anti-inflammatory Drugs (NSAIDs) Segment is Expected to Dominate the Market Over the Forecast Period
By drug type, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is anticipated to garner the largest market share. Nonsteroidal anti-inflammatory drugs (NSAIDs) refer to a drug class that reduces pain, decreases fever, prevents blood clots, and decreases inflammation in higher doses. NSAIDs block enzymes in the body that produce prostaglandins. Prostaglandins are a group of naturally occurring fatty acids that play a role in pain and inflammation. The goal of NSAID treatment for patients with idiopathic or viral pericarditis is to reduce symptoms. These drugs have similar efficacy, with about 85-90% of patients experiencing relief from chest pain within days of treatment.
According to the study titled "Advances in pharmacotherapy for acute and recurrent pericarditis," published in Expert Opinion on Pharmacotherapy in April 2022, for acute and recurrent pericarditis, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs), and colchicine is the first lines of treatments. In patients with multiple recurrences, drugs that block the NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome/interleukin-1 (IL-1) axis are beneficial. Thus, such studies are expected to drive the segment's growth over the forecast period.
Furthermore, according to the study titled "A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis" published in the Trends in Cardiovascular Medicine in February 2022, randomized controlled trials (RCTs) evaluating NSAIDs, indomethacin, colchicine, steroids, intravenous immunoglobulins, immunomodulators, or interleukin receptor antagonists in adult patients with acute idiopathic pericarditis are ongoing. Colchicine plus NSAIDS and anakinra were found to be effective in preventing Acute idiopathic pericarditis (AIP) recurrences.
Thus, all the aforementioned factors are expected to boost the segment's growth over the forecast period.
North America Dominates the Market and is Expected to do Same in the Forecast Period.
North America is anticipated to account for a major share of the global pericarditis drugs market during the forecast period. This is attributed to the large number of people diagnosed with cardiac disorders resulting in pericarditis, the presence of key market players, substantial R&D, and health care spending. Moreover, an increase in awareness about the pericardium inflammation associated with heart attacks in the patient population is expected to boost the growth of the market within North America.
According to the Centers for Disease Control and Prevention (CDC) 's article titled "Heart Disease Facts," updated in September 2020, heart disease is the leading cause of death in the United States. The same source also reports that every year, about 805,000 Americans have a heart attack. Moreover, as per the April 2020 data of the National Center for Health Statistics, the prevalence of age-adjusted hypertension in the United States was 45.4% in adults, 51% in men, and 39.7% in women. As pericarditis is mostly associated with heart diseases, the increasing prevalence of the diseased population is expected to drive the demand for its treatment, thereby boosting the market growth.
Additionally, a few of the key market players in the country are developing novel products and technologies to compete with the existing products, while others are acquiring and partnering with other companies operating in the market. For instance, in May 2021, the Food and Drug Administration (FDA) approved the first treatment for a disease that causes recurrent inflammation in the sac surrounding the heart. Arcalyst (rilonacept) injection has been approved by the FDA to treat recurrent pericarditis and reduce the risk of recurrence in adults and children aged 12 and up. In July 2020, Kiniksa Pharmaceuticals Ltd reported that the United States Food and Drug Administration (FDA) had granted orphan drug designation for rilonacept for the treatment of pericarditis, which includes recurrent pericarditis. Rilonacept is a weekly, subcutaneously injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling.
Thus, all the aforementioned factors are expected to boost the market growth in the region over the forecast period.
